|
|
Article: Study demonstrates long-term efficacy with indiplon modified release.
- Article from:
- Pain & Central Nervous System Week
- Article date:
- April 26, 2004
CopyrightCOPYRIGHT 2004 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
2004 APR 26 - (NewsRx.com & NewsRx.net) -- Neurocrine Biosciences, Inc., (NBIX) announced a second long-term phase III trial with highly positive efficacy results from its 3-month pivotal study, referred to as "SLEEP," the study of long-term efficacy and safety of indiplon modified release in primary (chronic) insomnia patients.
Preliminary results demonstrated that patients who took indiplon modified release either 20 mg or 30 mg nightly achieved rapid sleep onset, maintained high quality sleep throughout the night, and showed improvement in quality-of-life endpoints. Indiplon treatment demonstrated a highly statistically significant improvement in sleep for ...